External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics

The potential benefit of COLOFIT varied depending on FIT testing rates, the proportion of FIT ≥ 10 µg/g, and the symptoms in the tested population. Adopting COLOFIT into current clinical practice demands, therefore, FIT positivity of at least 17% and CRC rates within 1.3-1.6%. Further validation in local and different populations would also be of significant value and help to maximise COLOFIT's ability to improve diagnostic pathways.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2025-08-27
DOI
https://doi.org/10.1186/s12916-025-04339-w
Citations
2
Primary Topic
Colorectal Cancer Screening and Detection
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics

Colin John Rees, Kinga A. Várnai, Brian David Nicholson, Gary Abel et al.
2 citations
BMC Medicine
Colorectal Cancer Screening and Detection
2.09
article

External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics

Colin John Rees, Kinga A. Várnai, Brian David Nicholson, Gary Abel, Jim Davies, Hizni Salih, Eva Morris, Brian Shine, Theresa Noble, Joshua Withers, Tim James, Andres Tamm, William Hamilton, James E. East
article en
2 citations

Abstract

The potential benefit of COLOFIT varied depending on FIT testing rates, the proportion of FIT ≥ 10 µg/g, and the symptoms in the tested population. Adopting COLOFIT into current clinical practice demands, therefore, FIT positivity of at least 17% and CRC rates within 1.3-1.6%. Further validation in local and different populations would also be of significant value and help to maximise COLOFIT's ability to improve diagnostic pathways.

BMC MedicineVol. 23(1)
University of Exeter (GB), John Radcliffe Hospital (GB), Open Data Institute (GB), University of Oxford (GB), South Tyneside and Sunderland NHS Foundation Trust (GB), Oxford BioMedica (United Kingdom) (GB), Newcastle University (GB)
Cancer Research UK, National Institute for Health and Care Research, Engineering and Physical Sciences Research Council, NIHR Oxford Biomedical Research Centre
Openalex Percentile: Top 11%
Colorectal Cancer Screening and Detection
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.